MarketPeel
Insider Trading Intelligence
KV

Krishnan Viswanadhan

AGIO
CHIEF CORP DEV & STRATEGY · AGIOS PHARMACEUTICALS, INC. · CIK 0001999913
FILING MIX · LIFETIME58%/42%
BUYS
7
SELLS
5
TOTAL VALUE
$185.0K
COMPANIES
1
ACTIVE SINCE
Mar 2025
HOLDINGS NOW
3,000
AVG SELL PX
$31.26
TRADE KIND
SHOWING 12 / 12
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 6 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Krishnan Viswanadhan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%-3.40%+0.72%-4.12%-4.12%
14d2+50.00%+0.04%+1.92%-1.88%-1.88%
30d2+50.00%+3.58%+3.07%+0.51%+0.51%
60d2+100.00%-8.46%+5.39%-5.82%-5.82%
90d2+0.00%+4.61%+13.87%-5.80%-5.80%
180d2(2 pending)
1y2(2 pending)
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AGIO · 3,000 shares · as of Jun 18, 2026
013,84427,68741,53155,3742026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2025
2025
2025
2026
2026
FLOW · 7 buys / 5 sellsCOVERAGE · 6 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
3,0003,000Jun 18, 2026Jun 23, 2026View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Strategy and Operations
3,0009,000Jun 18, 2026Jun 23, 2026View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Corp Dev & Strategy
8,10013,241Apr 2, 2026Apr 6, 2026View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Corp Dev & Strategy
8,1008,100Apr 2, 2026Apr 6, 2026View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,959$34.71$102.7K10,282Apr 2, 2026Apr 6, 2026View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
2,959$27.80$82.3K5,141Mar 5, 2026Mar 9, 2026View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASE
Chief Corp Dev & Strategy
8,1008,100Mar 5, 2026Mar 9, 2026View →
AGIO
AGIOS PHARMACEUTICALS, INC.
SALE
Chief Corp Dev & Strategy
8,10016,200Mar 5, 2026Mar 9, 2026View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
14,00014,000Mar 1, 2026Mar 3, 2026View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
52,00052,000Mar 1, 2026Mar 3, 2026View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
24,30024,300Mar 5, 2025Mar 7, 2025View →
AGIO
AGIOS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
55,37455,374Mar 5, 2025Mar 7, 2025View →
Other insiders · AGIO
Loading peer insiders…
About this filer
CIK 0001999913
ROLE
Chief Corp Dev & Strategy
PRIMARY
AGIO
COMPANIES
1
ACTIVE SINCE
Mar 2025
MARKETPEEL · /INSIDER/0001999913DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback